# A Study to Evaluate the Efficacy and Safety of ENX-102 in Participants With Social Anxiety Disorder

> **NCT07193563** · PHASE2 · COMPLETED · sponsor: **Engrail Therapeutics INC** · enrollment: 47 (actual)

## Conditions studied

- Social Anxiety Disorder (SAD)

## Interventions

- **DRUG:** ENX-102
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT07193563
- **Lead sponsor:** Engrail Therapeutics INC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2025-09-05
- **Primary completion:** 2026-03-19
- **Final completion:** 2026-03-19
- **Target enrollment:** 47 (ACTUAL)
- **Last updated:** 2026-04-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07193563

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07193563, "A Study to Evaluate the Efficacy and Safety of ENX-102 in Participants With Social Anxiety Disorder". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07193563. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*